logo

With the rapid implementation of ‘targeted’ therapies, kidney cancer has entered a new era where old paradigms are being challenged, and new ones can be explored. The idea of deliv[...]
 Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study Abstract Objective To evaluate the ability of neoadjuvant axitinib to redu[...]